09.03.26 -- Catalent Says It's Not Our Facility; It Belongs To Novo Nordisk

Transferring cell cultures between scales is challenging and error-prone. See how bioreactor scaling software predicts optimal settings to enable efficient scale-up and faster progression to clinical studies.

Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.

What does the BATH-O-CARD acronym represent, and how can it help you during your aqueous cleaning process?

In today's fast-moving biopharma landscape, scaling from clinic to commercial takes more than expertise—see how collaboration can transform scale-up and drive confident progress.

Aligning early upstream choices, downstream purification, and analytical testing prevents scale-up delays, reduces process variability, and protects timelines for complex biologics.

A conversation on what drives CDMO success — from operational discipline and leadership to complex manufacturing challenges and industry trends.

Complex biologics need scalable, GMP-ready development from the start. Early decisions, scientific continuity, and strong partnerships help reduce delays and rework.

How strategic investments in development, manufacturing, and clinical supply are helping organizations reduce risk and accelerate drug development.

Deciding whether to stay or switch CDMOs means balancing continuity benefits, capability gaps, and transfer costs to ensure efficient, low-risk clinical-to-commercial progress.

Integrate a strategic intellectual property approach early in drug development to streamline research, uncover opportunities, and maximize the return on your investment.

Water for Injection is a critical, highly regulated component of sterile drug manufacturing. Outsourcing its production offers faster timelines, reduced risk, and improved operational and cost efficiency.

Learn how rational plasmid engineering and promoter optimization can boost AAV productivity while reducing plasmid burden — paving the way for more efficient, scalable viral vector manufacturing.

Uncover how modular N-1 perfusion strategies shorten seed train timelines and reduce facility strain — enabling upstream processes that scale efficiently and reliably for commercial manufacturing.

Despite challenges with mammalian host cell line diversity, Lonza's mitigation strategies drive efficiency and reproducibility, maximizing cell growth and product quality.

Administering high-dose biologics subcutaneously offers real benefits — reduced treatment burden, greater patient convenience, and improved adherence.

Explore the technologies driving the shift to microbial expression — and how the right outsourcing partner helps you capture the benefits of these therapeutics.